Brokerages Set Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Price Target at $38.64

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has earned a consensus rating of “Buy” from the fourteen research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $38.6364.

Several analysts have recently weighed in on CNTA shares. Wolfe Research initiated coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $40.00 price objective for the company. TD Cowen reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Guggenheim lifted their price objective on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Truist Financial raised their target price on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Finally, Wells Fargo & Company upped their price target on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th.

Insider Activity at Centessa Pharmaceuticals

In other news, insider Iqbal J. Hussain sold 38,951 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total value of $979,617.65. Following the transaction, the insider owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. The trade was a 40.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mario Alberto Accardi sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the insider directly owned 178,801 shares in the company, valued at $5,364,030. The trade was a 5.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 49,961 shares of company stock worth $1,304,878 in the last three months. 7.09% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. TD Waterhouse Canada Inc. acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth $25,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth about $36,000. T. Rowe Price Investment Management Inc. increased its stake in shares of Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after acquiring an additional 1,516 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Centessa Pharmaceuticals by 42.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after purchasing an additional 1,008 shares during the last quarter. Finally, Knott David M Jr acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth about $100,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock opened at $26.86 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. Centessa Pharmaceuticals has a one year low of $9.60 and a one year high of $30.58. The firm has a market cap of $3.92 billion, a PE ratio of -14.68 and a beta of 1.56. The stock’s fifty day moving average price is $24.36 and its two-hundred day moving average price is $23.63.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.